We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Accept Cookies
- 1-631-338-8059
info@cd-genomics.com
info@cd-genomics.com
CD Genomics ctDNA reference material stands as an exceptionally precise benchmark, bolstering the detection of mutations in cancer-associated cell and liquid biopsies. It encompasses a comprehensive array of 40 clinically significant mutations sourced from 28 genes spanning diverse cancer types. Our offering caters to diverse needs, with selectable allele frequency options ranging from 0%, 0.125%, 0.5%, 1%, to 2%.
Circulating Tumor DNA (ctDNA) reference materials play a pivotal role in advancing liquid biopsy research and Next Generation Sequencing (NGS). These reference materials are not just tools, but rather catalysts in the transformative journey of cancer diagnostics and treatment. By faithfully replicating key tumor variants and mutations, they provide researchers with a crucial standardized testing resource, ensuring the precision and dependability of liquid biopsy methods.
In the realm of liquid biopsy studies, ctDNA reference materials offer a spectrum of allele frequency options, enabling researchers to recreate diverse mutation scenarios. This, in turn, aids in fine-tuning and validating assays for optimal performance. Furthermore, their versatility is exemplified by the inclusion of clinically significant variants like EGFR exon 19 deletions and SNV BRAF c.1799T>A, opening doors to a wide array of applications within liquid biopsy research.
In the context of NGS, ctDNA reference materials assume an indispensable role by facilitating the testing and validation of novel sequencing methodologies and workflows. These materials enhance the precision and efficiency of sequencing processes. Their availability empowers researchers to generate copious amounts of high-quality data in a single assay, leading to substantial cost savings for laboratories and heightened research productivity.
Our CD ctDNA reference material finds widespread utility in the following areas:
Explore Our ctDNA (Circulating Tumor DNA) Reference Products:
| Cat. No. | Product Name | Brief Description | Inquiry | Basket |
|---|---|---|---|---|
| CTRM022 | CD ctDNA Mutation Mix AF1% | Our CD ctDNA Reference Material is a highly precise reference material, supporting the detection of mutations in cancer-related cells and liquid biopsies. Includes 25 clinically relevant mutations from 16 genes associated with various cancer types. Our product provides multiple allele frequency options, including 0.1%, 0.5%, 1%, 2.5% and 5%. | ||
| CTRM023 | CD ctDNA Mutation Mix AF0.5% | Our CD ctDNA Reference Material is a highly precise reference material, supporting the detection of mutations in cancer-related cells and liquid biopsies. Includes 25 clinically relevant mutations from 16 genes associated with various cancer types. Our product provides multiple allele frequency options, including 0.1%, 0.5%, 1%, 2.5% and 5%. | ||
| CTRM024 | CD ctDNA Mutation Mix AF0.1% | Our CD ctDNA Reference Material is a highly precise reference material, supporting the detection of mutations in cancer-related cells and liquid biopsies. Includes 25 clinically relevant mutations from 16 genes associated with various cancer types. Our product provides multiple allele frequency options, including 0.1%, 0.5%, 1%, 2.5% and 5%. | ||
| MCT001 | CD Myeloid ctDNA Mix WT | This product is tailored to empower laboratories in the realm of liquid biopsy testing for myeloids. CD Myeloid ctDNA Mix contains 25 DNA variants, including FLT3 ITDs, NPM1 and now EZH2 and IDH2. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. | ||
| MCT002 | CD Myeloid ctDNA Mix AF1% | This product is tailored to empower laboratories in the realm of liquid biopsy testing for myeloids. CD Myeloid ctDNA Mix contains 25 DNA variants, including FLT3 ITDs, NPM1 and now EZH2 and IDH2. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. | ||
| MCT003 | CD Myeloid ctDNA Mix AF0.5% | This product is tailored to empower laboratories in the realm of liquid biopsy testing for myeloids. CD Myeloid ctDNA Mix contains 25 DNA variants, including FLT3 ITDs, NPM1 and now EZH2 and IDH2. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. | ||
| MCT004 | CD Myeloid ctDNA Mix AF0.1% | This product is tailored to empower laboratories in the realm of liquid biopsy testing for myeloids. CD Myeloid ctDNA Mix contains 25 DNA variants, including FLT3 ITDs, NPM1 and now EZH2 and IDH2. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. | ||
| MCT005 | CD Myeloid Mutation DNA Mix | This product is tailored to empower laboratories in the realm of gene mutation detection for myeloids. CD Myeloid DNA Mix contains 23 DNA variants, including FLT3 ITDs and NPM1. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. | ||
| MCT006 | CD Myeloid Fusion RNA Mix | This product is tailored to empower laboratories in the realm of gene mutation detection for myeloids. CD Myeloid RNA Mix contains 9 RNA fusions, including BCR-ABL and PML-RARA. It serves the critical purpose of establishing the limit of detection (LOD) and validating the sensitivity of your laboratory's NGS-based detection methods. |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to info@cd-genomics.com for inquiries.
Please fill out the form below: ×
